Can tremelimumab/tremelimumab be used in combination with durvalide?

Tremelimumab can be used in combination with durvalumab. This combination has been widely recognized by the international oncology community and has shown good anti-tumor effects in clinical trials. Imrvalumab is an anti-PD-L1 monoclonal antibody that prevents tumors from evading immune surveillance by blocking the binding of PD-L1 to T cell receptors. Texitumumab activates T cells through the anti-CTLA-4 mechanism. The two complement each other and can significantly enhance the immune system's ability to recognize and kill tumors. This dual immune mechanism gives the combination regimen potential advantages in the treatment of unresectable hepatocellular carcinoma (uHCC) and metastatic non-small cell lung cancer (mNSCLC).

In the treatment of unresectable hepatocellular carcinoma, the regimen of temsilimumab combined with imrvalumab has been approved by the FDA. Combination therapy releases T cell suppression, enhances immune activation, and blocks the tumor's immune evasion mechanism, allowing patients to obtain a more durable immune response. This treatment strategy is particularly suitable for patients with limited response to traditional treatments, providing them with new treatment options. In metastatic non-small cell lung cancer, this combination regimen can also be used in combination with platinum-based chemotherapy drugs to form a comprehensive regimen of immunotherapy and chemotherapy. This not only enhances efficacy, but also provides patients with a multi-level treatment strategy that takes into account both short-term tumor control and long-term immune response.

In terms of mechanism, temtumumab relieves T cell inhibition by blockingCTLA-4, while imrvalumab prevents tumors from evading immune attack by inhibiting the PD-L1 pathway. The two complement each other to form a stronger anti-tumor immune environment. International multi-center clinical studies have shown that this combination immunotherapy exhibits controllable safety and good clinical potential in a variety of solid tumors. The combination regimen is not only superior to single-agent therapy in efficacy, but also provides clinical experience and scientific basis for future tumor-immune combination strategies.

Reference: https://www.drugs.com/mtm/tremelimumab.html